ecancer

ecancer.org

ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.

 

ecancer
Avatar

EHA 2021 Update on Fixed-Duration Ibrutinib and Venetoclax for 1L CLL: Primary Analysis of the GLOW Study

By ecancer FEATURING Arnon Kater
By ecancer FEATURING Arnon Kater
12 views
September 2, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

19:30
AstraZeneca Oncology

The Importance of HRD Testing in Advanced Ovarian Cancer

Feat. M. Markman

Featured Video

23:46
AstraZeneca Oncology

First-line Maintenance Treatment Option in Patients With HRD-Positiv…

Feat. S. Lewin
Leukemia
07:33

Epitope Editing Enables Targeted Immunotherapy of AML

ecancer

G. Casirati

22 views
04:14

ALPINE: A Randomized Phase 3 Study of Zanubrutinib vs. Ibrutinib for…

ecancer

J. Brown

506 views
04:55

First Results of a Head-to-Head Trial of Acalabrutinib vs. Ibrutinib…

ecancer

J. Byrd

405 views
04:36

Safety & Efficacy of Asciminib for Heavily Pretreated Patients With …

ecancer

M. Mauro

26 views
10:41

EHA 2021 Update on 1L Ibrutinib + Venetoclax for CLL/SLL: Primary An…

ecancer

J. Allan

22 views
05:12

EHA 2021 Update on Venetoclax + Obinutuzumab in Untreated CLL: 4-yea…

ecancer

O. Al-Sawaf

16 views
07:02

EHA 2021 Primary Analysis From the OPTIC Trial on CP-CML: A Dose-Ran…

ecancer

J. Cortés

27 views
07:36

EHA 2021 Update on Fixed-Duration Ibrutinib and Venetoclax for 1L CL…

ecancer

A. Kater

12 views
05:52

EHA 2021 Update on Blinatumomab for MRD-Positive B-Cell ALL

ecancer

N. Short

17 views
05:42

EHA 2021 Update on Blinatumomab + Ponatinib for Ph+ ALL: Interim Res…

ecancer

N. Short

127 views
09:22

EHA 2021 Update on KTE-X19, an Anti-CD19 CAR T-Cell Therapy for R/R …

ecancer

B. Shah

68 views
05:28

2020 ASH Update on IDH 1/2-Mutated AML: Does Ven+Aza vs. Aza Mono Im…

ecancer

H. Kantarjian

14 views